UAB Hematology Review 2021


 

2021 Updates on 2L CML and Beyond: TKIs (Imatinib, Dasatinib/Nilotinib/Bosutinib Continuation, Ponatinib), Omacetaxine, Asciminib, HQP1351

208 views
March 18, 2021
Comments 0
Login to view comments. Click here to Login